|
End-of-day quote
Other OTC
|
||
| - USD | - |
|
| Market Cap | 5.21M 4.58M 4.34M 3.92M 7.39M 499M 7.49M 51.96M 20M 255M 19.55M 19.12M 818M | P/E 2026 * |
-0.78x | P/E 2027 * | -0.68x |
|---|---|---|---|---|---|
| Enterprise Value | 5.21M 4.58M 4.34M 3.92M 7.39M 499M 7.49M 51.96M 20M 255M 19.55M 19.12M 818M | EV / Sales 2026 * |
260x | EV / Sales 2027 * | 3.71x |
| Free-Float |
96.68% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 57 | 31/08/2024 | |
Michael Shankman
DFI | Director of Finance/CFO | 66 | 01/10/2024 |
John Docherty
PSD | President | 55 | 15/04/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 65 | 26/10/2006 | |
Nicholas Baxter
BRD | Director/Board Member | 72 | 08/07/2011 |
John Docherty
BRD | Director/Board Member | 55 | 29/04/2016 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.61% | -2.58% | +39.49% | +113.89% | 1,031B | ||
| -0.81% | -3.08% | +41.01% | +69.09% | 638B | ||
| -0.48% | -1.92% | +6.41% | +75.41% | 462B | ||
| -0.45% | -2.28% | +60.43% | +41.00% | 359B | ||
| -0.13% | -4.21% | +23.31% | +40.33% | 335B | ||
| -1.68% | -0.94% | +13.29% | +26.21% | 273B | ||
| -1.68% | -2.73% | -3.01% | +10.16% | 253B | ||
| -1.68% | +2.33% | +39.20% | +56.03% | 228B | ||
| -0.86% | -1.35% | +32.86% | +99.28% | 185B | ||
| Average | -0.93% | -0.36% | +28.11% | +59.04% | 418.21B | |
| Weighted average by Cap. | -0.81% | -0.35% | +31.14% | +70.53% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 20K 17.61K 16.69K 15.06K 28.39K 1.92M 28.76K 200K 76.83K 980K 75.1K 73.46K 3.14M | 1.4M 1.24M 1.17M 1.06M 1.99M 135M 2.02M 14.01M 5.39M 68.77M 5.27M 5.15M 220M |
| Net income | -6.64M -5.85M -5.54M -5M -9.43M -637M -9.55M -66.27M -25.5M -325M -24.93M -24.39M -1.04B | -8.95M -7.88M -7.46M -6.74M -12.7M -858M -12.87M -89.31M -34.37M -439M -33.6M -32.86M -1.41B |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
Select your edition
All financial news and data tailored to specific country editions
















